| Literature DB >> 21849459 |
Joseph E Blaney1, Christoph Wirblich, Amy B Papaneri, Reed F Johnson, Carey J Myers, Terry L Juelich, Michael R Holbrook, Alexander N Freiberg, John G Bernbaum, Peter B Jahrling, Jason Paragas, Matthias J Schnell.
Abstract
The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21849459 PMCID： PMC3187516 DOI： 10.1128/JVI.00558-11
Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103